{"id":34486,"date":"2026-08-25T11:28:09","date_gmt":"2026-08-25T14:28:09","guid":{"rendered":"https:\/\/ptbr.idor.org\/?post_type=ensaio_clinico&#038;p=34486"},"modified":"2026-08-25T11:28:09","modified_gmt":"2026-08-25T14:28:09","slug":"zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/","title":{"rendered":"ZENITH (ALN-AGT01-008) &#8211; Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV"},"content":{"rendered":"<p><span data-olk-copy-source=\"MessageBody\">Avaliar a efic\u00e1cia e a seguran\u00e7a de Zilebesiran adicionalmente ao padr\u00e3o de tratamento na redu\u00e7\u00e3o de eventos adversos cardiovasculares importantes.<\/span><\/p>\n<p><span data-olk-copy-source=\"MessageBody\">ClinicalTrials.gov: NCT07181109<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avaliar a efic\u00e1cia e a seguran\u00e7a de Zilebesiran adicionalmente ao padr\u00e3o de tratamento na redu\u00e7\u00e3o de eventos adversos cardiovasculares importantes. ClinicalTrials.gov: NCT07181109<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-34486","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ZENITH (ALN-AGT01-008) - Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZENITH (ALN-AGT01-008) - Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Avaliar a efic\u00e1cia e a seguran\u00e7a de Zilebesiran adicionalmente ao padr\u00e3o de tratamento na redu\u00e7\u00e3o de eventos adversos cardiovasculares importantes. ClinicalTrials.gov: NCT07181109\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\\\/\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\\\/\",\"name\":\"ZENITH (ALN-AGT01-008) - Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/#website\"},\"datePublished\":\"2026-08-25T14:28:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"ZENITH (ALN-AGT01-008) &#8211; Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/#website\",\"url\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZENITH (ALN-AGT01-008) - Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/","og_locale":"pt_BR","og_type":"article","og_title":"ZENITH (ALN-AGT01-008) - Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Avaliar a efic\u00e1cia e a seguran\u00e7a de Zilebesiran adicionalmente ao padr\u00e3o de tratamento na redu\u00e7\u00e3o de eventos adversos cardiovasculares importantes. ClinicalTrials.gov: NCT07181109","og_url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/","url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/","name":"ZENITH (ALN-AGT01-008) - Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/#website"},"datePublished":"2026-08-25T14:28:09+00:00","breadcrumb":{"@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/zenith-aln-agt01-008-hipertensao-nao-controlada-com-dcv-estabelecida-ou-com-alto-risco-de-dcv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"ZENITH (ALN-AGT01-008) &#8211; Hipertens\u00e3o n\u00e3o controlada com DCV estabelecida ou com alto risco de DCV"}]},{"@type":"WebSite","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/#website","url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/34486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=34486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}